J M Horacek1, T Kupsa1, M Vasatova2, L Jebavy1, P Zak3. 1. Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic. 2. Institute of Clinical Biochemistry and Diagnostics, University Hospital and Charles University, Faculty of Medicine in Hradec Kralove, Czech Republic. 3. 4th Department of Internal Medicine - Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic.
Abstract
AIM: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) and in healthy subjects using biochip array technology. METHODS: A total of 15 AML patients and 15 healthy subjects (blood donors) were studied. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This approach allows multi-analytical determination from a single sample. T-tests were used for statistical analysis. RESULTS: In newly diagnosed AML patients, we found significant increase (p < 0.01) in serum VCAM-1, ICAM-1, E-selectin, L-selectin, and significant increase (p < 0.05) in serum IL-6, IL-8. No significant differences were found in the levels of other evaluated cytokines and adhesion molecules. CONCLUSION: Our results indicate that serum levels of specific cytokines and adhesion molecules (VCAM-1, ICAM-1, E-selectin, L-selectin, IL-6, IL-8) are significantly altered in patients with newly diagnosed AML, showing activity of the disease. Whether these alterations could serve as a prognostic marker for AML is not known. Further studies will be needed to define the potential role of these and additional markers in the risk stratification of AML.
AIM: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) and in healthy subjects using biochip array technology. METHODS: A total of 15 AMLpatients and 15 healthy subjects (blood donors) were studied. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This approach allows multi-analytical determination from a single sample. T-tests were used for statistical analysis. RESULTS: In newly diagnosed AMLpatients, we found significant increase (p < 0.01) in serum VCAM-1, ICAM-1, E-selectin, L-selectin, and significant increase (p < 0.05) in serum IL-6, IL-8. No significant differences were found in the levels of other evaluated cytokines and adhesion molecules. CONCLUSION: Our results indicate that serum levels of specific cytokines and adhesion molecules (VCAM-1, ICAM-1, E-selectin, L-selectin, IL-6, IL-8) are significantly altered in patients with newly diagnosed AML, showing activity of the disease. Whether these alterations could serve as a prognostic marker for AML is not known. Further studies will be needed to define the potential role of these and additional markers in the risk stratification of AML.
Authors: Petra Aigner; Tatsuaki Mizutani; Jaqueline Horvath; Thomas Eder; Stefan Heber; Karin Lind; Valentin Just; Herwig P Moll; Assa Yeroslaviz; Michael J M Fischer; Lukas Kenner; Balázs Győrffy; Heinz Sill; Florian Grebien; Richard Moriggl; Emilio Casanova; Dagmar Stoiber Journal: Blood Adv Date: 2019-07-09
Authors: Pierre Peterlin; Joelle Gaschet; Thierry Guillaume; Alice Garnier; Marion Eveillard; Amandine Le Bourgeois; Michel Cherel; Camille Debord; Yannick Le Bris; Olivier Theisen; Catherine Godon; Béatrice Mahé; Viviane Dubruille; Soraya Wuilleme; Cyrille Touzeau; Thomas Gastinne; Nicolas Blin; Anne Lok; Benoît Tessoulin; Steven Le Gouill; Philippe Moreau; Marie-C Béné; Patrice Chevallier Journal: Cancer Med Date: 2020-12-25 Impact factor: 4.452